微泰医疗-B公告2026年上半年收入同比至少增长63%并扭亏为盈

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# MicroTech Medical (Hangzhou) Co., Ltd.

# 微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司

(A joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock code: 2235)

## POSITIVE PROFIT ALERT

This announcement is made by MicroTech Medical (Hangzhou) Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “Board”) of directors (the “Directors”) of the Company hereby informs the shareholders of the Company (the “Shareholders”) and potential investors that, based on the preliminary review on the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the “Reporting Period”) pursuant to the Accounting Standards for Business Enterprises promulgated by the Ministry of Finance of the PRC and relevant requirements, the estimated results are as follows:

- 1) It is estimated that the income of the Group during the Reporting Period will amount to not less than RMB400 million, representing a year-on-year increase of no less than approximately 63% as compared to RMB246 million for the six months ended June 30, 2025.
- 2) It is estimated that the Group will realize a net profit attributable to owners of the parent company of not less than RMB36 million during the Reporting Period, representing a turnaround from loss to profit as compared to RMB-2 million for the six months ended June 30, 2025.


The aforementioned expected growth is mainly attributable to:

- 1) the income from the sales of continuous glucose monitoring system (CGMS), one of the Group’s pivotal products, demonstrated continuous strong growth, while products including the patch insulin pump system and blood glucose monitoring system maintained sustained and robust development;
- 2) the rising revenue contribution of continuous glucose monitoring system and the improvement of production scale efficiency drove a significant uplift in the overall gross profit margin as compared to the same period last year; and
- 3) Operational efficiency recorded a remarkable improvement, marketing activities were continuously optimised, the proportion of selling expenses and administrative expenses to income realized a significant decrease.


As the unaudited consolidated financial results of the Group for the Reporting Period have not yet been finalized, information contained in this announcement is based on information currently available to the Board and the preliminary unaudited consolidated management accounts of the Group for the Reporting Period, such information has not yet been reviewed by auditor or the audit committee of the Company. The actual financial results of the Group for the Reporting Period are subject to adjustment and may differ from information contained in this announcement. Such results are expected to be published by the end of August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board MicroTech Medical (Hangzhou) Co., Ltd. Zheng Pan Chairman of the Board

Hangzhou, the PRC, July 30, 2026

As at the date of this announcement, the executive Directors are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.